Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen

<p>Abstract</p> <p>Background</p> <p>The R122H mutation of the cationic trypsinogen was found in patients with hereditary pancreatitis. A transgenic animal carrying this mutation could be useful as a genetic model system of pancreatitis.</p> <p>Methods</p...

Full description

Bibliographic Details
Main Authors: Mössner Joachim, Savkovic Vuk, Klöppel Günter, Gaiser Sebastian, Sack Ulrich, Selig Lena, Keim Volker, Bödeker Hans
Format: Article
Language:English
Published: BMC 2006-10-01
Series:BMC Gastroenterology
Online Access:http://www.biomedcentral.com/1471-230X/6/30
_version_ 1811284571618017280
author Mössner Joachim
Savkovic Vuk
Klöppel Günter
Gaiser Sebastian
Sack Ulrich
Selig Lena
Keim Volker
Bödeker Hans
author_facet Mössner Joachim
Savkovic Vuk
Klöppel Günter
Gaiser Sebastian
Sack Ulrich
Selig Lena
Keim Volker
Bödeker Hans
author_sort Mössner Joachim
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>The R122H mutation of the cationic trypsinogen was found in patients with hereditary pancreatitis. A transgenic animal carrying this mutation could be useful as a genetic model system of pancreatitis.</p> <p>Methods</p> <p>Mice transgenic for the human R122H cationic trypsinogen were generated using the -205 fragment of the rat elastase promoter. The presence of the transgene was assayed in the DNA, in pancreatic mRNA and in zymogen granule lysates. Serum levels of amylase, lipase and cytokines (MCP-1, IL-6) were monitored and the histological appearance of the tissue was investigated. Pancreatitis was induced by 7 hourly injections of 50 μg/kg cerulein. The procedure was repeated twice weekly for 10 consecutive weeks. The animals were sacrificed 24 (n = 8) and 48 hours (n = 8) after the first injection and at the end of the whole treatment (n = 7).</p> <p>Results</p> <p>The transgene was detected at the genomic level and in pancreatic mRNA. The corresponding protein was found in low amounts in zymogen granule lysates. R122H mice showed elevated pancreatic lipase, but there was no spontaneous development of pancreatitis within 18 months. After induction of pancreatitis, levels of lipase (after 24 hours) and amylase (after 48 hours) were higher in R122H mice compared to controls. Repeated treatment with cerulein resulted in a slightly more severe pancreatitis in R122H animals. Amylase, lipase, and the cytokine levels were similar to controls.</p> <p>Conclusion</p> <p>The R122H transgenic mouse failed to develop a spontaneous pancreatitis but a repeatedly provoked cerulein-induced pancreatitis led to a slightly more severe pancreatitis. The rather small difference in comparison to controls could be due to the low expression of the transgene in the mouse pancreas.</p>
first_indexed 2024-04-13T02:30:43Z
format Article
id doaj.art-d7cfdaf4e2524c79815ffc354eda8f39
institution Directory Open Access Journal
issn 1471-230X
language English
last_indexed 2024-04-13T02:30:43Z
publishDate 2006-10-01
publisher BMC
record_format Article
series BMC Gastroenterology
spelling doaj.art-d7cfdaf4e2524c79815ffc354eda8f392022-12-22T03:06:35ZengBMCBMC Gastroenterology1471-230X2006-10-01613010.1186/1471-230X-6-30Characterisation of a transgenic mouse expressing R122H human cationic trypsinogenMössner JoachimSavkovic VukKlöppel GünterGaiser SebastianSack UlrichSelig LenaKeim VolkerBödeker Hans<p>Abstract</p> <p>Background</p> <p>The R122H mutation of the cationic trypsinogen was found in patients with hereditary pancreatitis. A transgenic animal carrying this mutation could be useful as a genetic model system of pancreatitis.</p> <p>Methods</p> <p>Mice transgenic for the human R122H cationic trypsinogen were generated using the -205 fragment of the rat elastase promoter. The presence of the transgene was assayed in the DNA, in pancreatic mRNA and in zymogen granule lysates. Serum levels of amylase, lipase and cytokines (MCP-1, IL-6) were monitored and the histological appearance of the tissue was investigated. Pancreatitis was induced by 7 hourly injections of 50 μg/kg cerulein. The procedure was repeated twice weekly for 10 consecutive weeks. The animals were sacrificed 24 (n = 8) and 48 hours (n = 8) after the first injection and at the end of the whole treatment (n = 7).</p> <p>Results</p> <p>The transgene was detected at the genomic level and in pancreatic mRNA. The corresponding protein was found in low amounts in zymogen granule lysates. R122H mice showed elevated pancreatic lipase, but there was no spontaneous development of pancreatitis within 18 months. After induction of pancreatitis, levels of lipase (after 24 hours) and amylase (after 48 hours) were higher in R122H mice compared to controls. Repeated treatment with cerulein resulted in a slightly more severe pancreatitis in R122H animals. Amylase, lipase, and the cytokine levels were similar to controls.</p> <p>Conclusion</p> <p>The R122H transgenic mouse failed to develop a spontaneous pancreatitis but a repeatedly provoked cerulein-induced pancreatitis led to a slightly more severe pancreatitis. The rather small difference in comparison to controls could be due to the low expression of the transgene in the mouse pancreas.</p>http://www.biomedcentral.com/1471-230X/6/30
spellingShingle Mössner Joachim
Savkovic Vuk
Klöppel Günter
Gaiser Sebastian
Sack Ulrich
Selig Lena
Keim Volker
Bödeker Hans
Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen
BMC Gastroenterology
title Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen
title_full Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen
title_fullStr Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen
title_full_unstemmed Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen
title_short Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen
title_sort characterisation of a transgenic mouse expressing r122h human cationic trypsinogen
url http://www.biomedcentral.com/1471-230X/6/30
work_keys_str_mv AT mossnerjoachim characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT savkovicvuk characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT kloppelgunter characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT gaisersebastian characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT sackulrich characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT seliglena characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT keimvolker characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen
AT bodekerhans characterisationofatransgenicmouseexpressingr122hhumancationictrypsinogen